{"entity":{"id":"nct02503423","kind":"trial","name":"Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas","aka":[],"tldr":"A phase 1/2 trial of ASTX660 in non-Hodgkin lymphoma, run by Taiho Oncology, Inc., active and no longer recruiting.","summary":"Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas is a phase 1/2 interventional study registered as NCT02503423 by Taiho Oncology, Inc., with 253 participants enrolled, started 2015-07-14 and due to reach its primary completion in 2022-10. Interventions recorded: ASTX660.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT02503423","url":"https://clinicaltrials.gov/study/NCT02503423"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["araris"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT02503423","phase":"1/2","setting":"Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas","sponsor":"Taiho Oncology, Inc.","enrolled":253,"outcomes":[]},"route":"/trials/nct02503423/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"company":[{"id":"araris","kind":"company","name":"Araris Biotech (Taiho)","route":"/companies/araris/"}]}}